4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors

Carlotta GranchiDepartment of Pharmacy, University of Pisa, Pisa, Italy and

Flavio RizzolioSbarro Institute for Cancer Research and Molecular Medicine Center for Biotechnology, Temple University, Philadelphia, PA, USA

Vittorio BordoniDepartment of Pharmacy, University of Pisa, Pisa, Italy and

Isabella CaligiuriSbarro Institute for Cancer Research and Molecular Medicine Center for Biotechnology, Temple University, Philadelphia, PA, USA

Clementina ManeraDepartment of Pharmacy, University of Pisa, Pisa, Italy and

Marco MacchiaDepartment of Pharmacy, University of Pisa, Pisa, Italy and

Filippo MinutoloDepartment of Pharmacy, University of Pisa, Pisa, Italy and

Adriano MartinelliDepartment of Pharmacy, University of Pisa, Pisa, Italy and

Antonio GiordanoSbarro Institute for Cancer Research and Molecular Medicine Center for Biotechnology, Temple University, Philadelphia, PA, USA

Tiziano TuccinardiDepartment of Pharmacy, University of Pisa, Pisa, Italy and ;Sbarro Institute for Cancer Research and Molecular Medicine Center for Biotechnology, Temple University, Philadelphia, PA, USACorrespondence[email protected]

show all

4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date